MISSISSAUGA, Ontario--(BUSINESS WIRE)--The Goldfarb Corporation (“Goldfarb”), and Covalon Technologies Ltd. ("Covalon") (TSXV:COV), an advanced medical technologies company, announce, pursuant to National Instrument 62‐103, that Goldfarb has acquired 967,650 common shares in the capital of Covalon by exercising 967,650 purchase warrants of Covalon.
As a result of the exercised warrants, Goldfarb has increased their holdings to 2,056,655 common shares of Covalon (from 7.55% to 10.68% of its total issued and outstanding shares). Goldfarb may from time to time acquire additional securities of Covalon, dispose of some or all of the existing or additional securities held or will hold or may continue to hold their current position. Goldfarb is relying on the private agreement exemption to takeover bid rules.
Goldfarb has filed the required early warning report which is available on Covalon’s SEDAR profile at www.sedar.com.